Establishing a Tumor Registry of Patients With Mesonephric-like Adenocarcinoma (MLA)

Recruiting

• Conditions: Mesonephric-like Adenocarcinoma

• Registration Number: NCT06377527
• Lead Sponsor: M.D. Anderson Cancer Center

Brief Summary

To develop a database of medical information about patients with MLA in an effort to increase our understanding of the characteristics of MLA, which is the rarest form of endometrial carcinoma.

Detailed Description

Primary Objectives

1. To collect, both prospectively and retrospectively, data on participants characteristics, disease characterization, pathology and molecular data, treatment, and outcomes for participants with gynecologic mesonephric-like adenocarcinoma (MLA).

Secondary Objectives

1. To organize clinical information to support multifaceted queries of participant characteristics, treatment, and disease outcome data and to facilitate correlation of these characteristics with participant outcome.

2. To have a single data repository kept on a secure platform that will integrate clinical information and research findings and serve as an archive for future research.

Study Timeline

• Study First Submitted: 2024-04-16
• Study First Submitted QC: 2024-04-19
• Study First Posted: 2024-04-22
• Study Start: 2024-07-10
• Status Verified: 2025-05
• Last Update Submitted: 2025-05-12
• Last Update Posted: 2025-05-13
• Primary Completion: 2035-12-28
• Study Completion: 2037-12-28

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 2000

Inclusion Criteria

1. Adult patients with a diagnosis of gynecologic mesonephric-like adenocarcinoma (MLA).
2. Patients can also be diagnosed with mesonephric adenocarcinoma (MA) or patients with mesonephric and mesonephric-like carcinosarcomas.
3. Patients who are receiving or have received treatment at any facility, including but not limited to MD Anderson Cancer Center are eligible.
4. Patients may be residents of any country and be of any ethnic background.
5. Patients who request to participate in the registry, regardless of the method by which they learned of it, are eligible to participate.
6. Patients who do not speak English can be eligible if accompanied by an institutional interpreter.

Exclusion Criteria

1. Patients with other subtypes of EACs.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Tumor Registry	Through study completion; an average of 1 year	The goal of this data collection study is to develop a database (i.e. a registry/repository) of medical information about patients with MLA in an effort to increase our understanding of the characteristics of MLA, which is the rarest form of endometrial carcinoma.

Trial Locations

Locations (1)

MD Anderson Cancer Center; 🇺🇸 Houston, Texas, United States